Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6212686 | 1.00 | FUCA1 (0.47) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL28145499 | 0.91 | ACHE (0.49) | SIGMAR1DRD2DRD3ACHEBCHE | |
| SCHEMBL4303371 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL1724302 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL1983745 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL13992425 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL4304653 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| SCHEMBL697958 | 0.91 | FUCA1 (0.45) | FUCA1SIGMAR1DRD2DRD3ACHE | |
| Hydrochloric Acid SCHEMBL30938591 | 0.89 | SIGMAR1 (0.48) | SIGMAR1DRD2DRD3ACHEBCHE | |
| Hydrochloric Acid SCHEMBL2348540 | 0.89 | FUCA1 (0.44) | FUCA1SIGMAR1DRD2DRD3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138843-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | Medshine Discovery Inc. (CN) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-02-09 | — | — | US | disclosed |
| WO-2015165341-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037050-A1 | ISOQUINOLINESULFONYL DERIVATIVE AS RHO KINASE INHIBITOR | ROCK1, ROCK2, CIT | FUCA1 4544/4885SIGMAR1 2853/4885DRD2 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.